Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Biotechnology

Opinion: BIO CEO Jim Greenwood on ‘Don’t Let Fear Trump Science – Vaccinate Your Child’

Jim Greenwood

Washington, DC, November 26, 2017Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood wrote the following op-ed that was published in The Philadelphia Inquirer on August 23:

The nice lady had sugar cubes. My classmates and I lined up, single file, at Richboro Elementary School more than half a century ago, waiting for our taste. For a kid, it was a serendipitous moment — our parents were actually ordering us to consume sweets to keep us healthy.

These were no ordinary sugar cubes, though. We were in line to take the new oral polio vaccine. Continue reading

BIO Releases Plan to Unleash Innovation in Fight Against Opioid Abuse and Addiction

Washington, DC, November 9, 2017 — The Biotechnology Innovation Organization (BIO) on November 2 released a set of priorities for unleashing the power of innovation to develop solutions to prescription opioid abuse and addiction.

Many of BIO’s priorities align with recommendations put forth on November 1 by the President’s Commission on Combating Drug Addiction and the Opioid Crisis, including proposals to ensure that patients have comprehensive access to appropriate treatments, and increasing support for basic research to improve our understanding of the biology of pain and addiction.

Such recommendations outlined by the Commission include: Continue reading

Princeton University Panel Concludes that Mix of Biotech, Data Science Is Promising for Better Health and Business Growth in NJ

Princeton, NJ, November 1, 2017 — Steven Schultz reports for Princeton University’s Office of Engineering Communications that companies and academic institutions of New Jersey have a unique opportunity to solve health care problems and grow new businesses at the intersection of biotechnology and data science, a panel of leaders from industry and academia concluded at a conference convened by Princeton University on Oct. 25.

The event was organized by Princeton University’s Office of Corporate Engagement and Foundation Relations with the School of Engineering and Applied Science.

“It is a critical time in New Jersey,” said Debbie Hart, president and CEO of BioNJ, an industry group for biotechnology and life sciences companies. “We are at a tipping point where there are a number of things stacked up about to happen that will make a big difference.” Continue reading

At BioNJ Roundtable, Biopharmaceutical Executives Share What’s Behind Drug Pricing

Newark, NJ, October 3, 2017 — Vince Calio reports on NJBIZ that it’s no secret that biopharmaceutical companies have become the target of heavy criticism from politicians and consumers due to high drug prices, especially at a time when health care reform in the U.S. has become a hot-button topic.

The topic is especially of interest in New Jersey, given that some of the state’s largest employers are biopharmaceutical companies including Kenilworth-based Merck; Johnson & Johnson, headquartered in New Brunswick; and Celgene, located in Summit. Continue reading

BIO Report Finds Bioscience Drives Economic Growth in States Across U.S.

Washington, DC, September 20, 2017 — A report from Biotechnology Innovation Organization (BIO) unveiled in June concludes that the bioscience industry has had a positive impact on states’ economies and continues to be a driver of economic growth.

According to the new BIO report released in June, state lawmakers have recognized the importance of the industry, the authors state, and have responded to challenges facing the bioscience companies with legislative efforts focused on a supportive business climate. Continue reading

FDA Commissioner Vows Modernization to Keep Up with Biotech Advances

FDA Commissioner Scott Gottlieb, M.D.

Washington, DC, September 11, 2017 — Michelle Cortez reports on Bloomberg that a week after its landmark approval of the first treatment that works by genetically altering a patient’s cells, the Food and Drug Administration (FDA) vowed to modernize to keep up with the fast-moving field of biotechnology research.

FDA Commissioner Scott Gottlieb, M.D., on September 7 said, “We are at a point in the history of medicine that is similar to other great inflections in science where fundamental principles of science and medicine became firmly established as part of a leap in public health.” Continue reading

NJ EDA to Make Additional Lab Space Available for State’s Biotechnology Companies

Trenton, NJ, August 31, 2017 — The New Jersey Economic Development Authority (EDA) on August 17 announced it will again expand its successful incubator program with the creation of the Biotechnology Development Center (BDC) on the 50-acre Technology Centre of New Jersey research park in North Brunswick.

The BDC will offer suites of intermediate lab and office space from 3,400 to 10,000 square feet for emerging life sciences companies including those that have outgrown incubator space and other early stage companies looking to expand.

More than 32,600 square feet of new space is now available at the BDC. Continue reading

NJEDA to Make Additional Lab Space Available for State’s Growing Biotechnology Companies

Trenton, NJ, August 18, 2017 — The New Jersey Economic Development Authority (EDA) yesterday announced it will again expand its successful incubator program with the creation of the Biotechnology Development Center (BDC) on the 50-acre Technology Centre of New Jersey research park in North Brunswick.

The BDC will offer suites of intermediate lab and office space from 3,400 to 10,000 square feet for emerging life sciences companies including those that have outgrown incubator space and other early stage companies looking to expand. More than 32,600 square feet of new space is now available at the BDC. Continue reading

Life Sciences Talent Network Shaping Future Leaders in NJ’s Biotech Industry

Trenton, NJ, August 16, 2017Matt Alcalde, Director of Life Sciences Talent Network at BioNJ, writes:

Now in its second year, the Life Sciences Talent Advisory Board, managed by the Life Sciences Talent Network at BioNJ, has engaged over 100 employers from New Jersey’s robust health and life sciences industry.

These employers include pharmaceutical, biotechnology and medical device companies that are researching and developing new drugs and therapies to treat various diseases affecting patients worldwide as well as others who are supporting that work. Continue reading

Commercial Center for Innovative Technologies Adds Genomic Prediction, A Startup Fertility Treatment Company

North Brunswick, NJ, August 3, 2017 — Vince Calio reports in NJBIZ that the Commercial Center for Innovative Technologies has a new addition to its family, as Genomic Prediction, a startup fertility treatment company, has moved into the space — and is growing already.

The company was co-founded by Rutgers University associate professor Nathan Treff, and specializes in testing human embryos for a range of chromosomal abnormalities and genetic disorders before they are implanted in women who are seeking in vitro fertilization to become pregnant.

So far, the company’s long-term focus is on developing polygenic tests to predict the risk of diabetes and other conditions. Continue reading